Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Glaukos set the terms for its pending initial public offering, saying it plans to float nearly 5.4 million shares at $13 to $15 apiece.
At the midpoint of the range, the IPO would fetch $75.0 million. Laguna Hills, Calif.-based Glaukos initially said the offering could gross as much as $86.2 million. The IPO also includes a 30-day underwriters over-allotment option for another 803.700 shares of the stock, which is slated to trade on the New York Stock Exchange under the “GKOS” symbol. Read more
Sanovas said that it won FDA 510(k) clearance for its PulmoVia working channel, part of its platform designed to improve diagnostic and therapeutic interventions in the lung.
Working channels are normally integrated into bronchoscopes with optics as 1 piece, but the PulmoVia working channel is separate, CEO Larry Gerrans told MassDevice.com. Read more
Invuity priced its initial public offering at $12 a share, under the range the advanced surgical lighting maker set earlier in June, looking to raise $48 million.
Invuity shares are slated to begin trading under the “IVTY” symbol on the NASDAQ exchange, the company said. Read more